Thrombomodulin can predict the incidence of second events in patients with acute coronary syndrome: Single-center, retrospective cohort study.

[1]  L. Lerman,et al.  Secondary prevention strategy of cardiovascular disease using endothelial function testing. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[2]  K. Tabei,et al.  Japanese Society for Dialysis Therapy Clinical Guideline for “Maintenance Hemodialysis: Hemodialysis Prescriptions” , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  P. Serruys,et al.  Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT Study). , 2014, The American journal of cardiology.

[4]  M. Jeong,et al.  The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention , 2013, Korean circulation journal.

[5]  J. Lucas,et al.  Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor , 2012, Thrombosis and Haemostasis.

[6]  P. Chang,et al.  Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. , 2011, Cardiovascular research.

[7]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[8]  R. Rubinshtein,et al.  Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. , 2010, European heart journal.

[9]  J. Jansson,et al.  Thrombomodulin as a marker for bleeding complications during warfarin treatment. , 2009, Archives of internal medicine.

[10]  İ. Barutçu,et al.  Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study , 2008, Coronary artery disease.

[11]  J. Granada,et al.  The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[12]  A. Branzi,et al.  Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. , 2007, European heart journal.

[13]  V. Pasceri,et al.  Impaired Flow-Mediated Dilation and Risk of Restenosis in Patients Undergoing Coronary Stent Implantation , 2005, Circulation.

[14]  H. White,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes , 2004, Circulation.

[15]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[16]  N. Kipshidze,et al.  Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. , 2004, Journal of the American College of Cardiology.

[17]  Ping-Yen Liu,et al.  Elevation of the soluble thrombomodulin levels is associated with inflammation after percutaneous coronary interventions , 2004, Clinical cardiology.

[18]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[19]  Amir Lerman,et al.  Coronary Endothelial Dysfunction Is Associated With an Increased Risk of Cerebrovascular Events , 2003, Circulation.

[20]  Michael T. Watkins,et al.  Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease , 2003 .

[21]  S. Horie,et al.  Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[23]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[24]  L. Lai,et al.  [Relationship between hot spot mutation in hepatitis B virus basic core promotor and HBeAg status]. , 2000, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University.

[25]  H. Tomoda,et al.  Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. , 2000, American heart journal.

[26]  P. Grant,et al.  Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.

[27]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[28]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[29]  I. Miyamori,et al.  Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[30]  A. Blann,et al.  Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease , 1997, European journal of clinical investigation.

[31]  C. McCollum,et al.  Prognostic value of increased soluble thrombomodulin and increased soluble E‐selectin in ischaemic heart disease , 1997, European journal of haematology.

[32]  S. Ishiwata,et al.  Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. , 1997, American heart journal.

[33]  P. Groop,et al.  Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. , 1996, Circulation.

[34]  A. Quyyumi,et al.  The Role of Nitric Oxide in Endothelium‐Dependent Vasodilation of Hypercholesterolemic Patients , 1993, Circulation.

[35]  T. Strom,et al.  Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. , 1990, The Journal of biological chemistry.

[36]  A. Quyyumi,et al.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.

[37]  K. Shimada,et al.  Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[38]  J. Vita.  Endothelial Function , 2011, Circulation.

[39]  C. Stefanadis,et al.  Endothelial function and inflammation in coronary artery disease. , 2006, Heart.

[40]  H. Toyoshima,et al.  Event rates of acute myocardial infarction and coronary deaths in Niigata and Nagaoka cities in Japan. , 2003, Circulation journal : official journal of the Japanese Circulation Society.